openPR Logo
Press release

Pancreatic Cancer Therapeutics Market Overview and Regional Outlook Study

Pancreatic Cancer Therapeutics Market

Pancreatic Cancer Therapeutics Market

Pancreatic cancer is characterized by the uncontrolled growth of cells, i.e., malignant cells in the tissues of the pancreas. The malignant cells lead to the formation of tumors in the pancreas which deters the normal functioning of the organ.

Pancreatic cancer is a key challenge in the U.S. with presence of the highest number of pancreatic cancer patients in the world. It is estimated that in the country, 53,670 new cases of pancreatic cancer are likely to be diagnosed in 2017. Patients with pancreatic cancer have the lowest survival rate of all cancers. Over the last 40 years, survival has improved for most of the cancers but not for pancreatic cancer. This cancer is the third leading cause of cancer-related death in the U.S., surpassing breast cancer, in 2016.

View Report Overview -

Factors such as high unmet therapy needs in the overall oncology market, rising concerns across the world, and new developments in this field of treatment are contributing to the growth of the global Pancreatic Cancer Therapeutics Market. However, technologies for the timely diagnosis of this cancer type are yet to develop fully. Hence, a majority of pancreatic cancer patients are being diagnosed at an advanced stage of the disease. In the advanced stage of this cancer type, the treatment options are less, resulting in high mortality rates. These factors are limiting the growth of the market for pancreatic cancer therapeutics. Estimates show that only a small percentage (about 12% to 15%) of patients is diagnosed early enough to be treated with surgical procedures, drugs, and chemotherapy.

Pancreatic cancer occurs in exocrine cells which produce digestive juices or endocrine cells that secrets hormones regulating blood sugars. The global pancreatic cancer therapeutics market is segmented based on whether the cancer affects endocrine or exocrine functions.

Adenocarcinoma, which constitutes nearly 95% of all exocrine pancreatic cancers, is the most common pancreatic cancer type. Other prevalent cancers of the pancreas include pancreatic neuroendocrine tumors (NETs), gastrinoma (Zollinger-Ellison syndrome), glucagonoma, insulinoma, VIPoma (Verner-Morrison syndrome), and multiple endocrine neoplasia type-1 (MEN1). In terms of treatment, the pancreatic cancer therapeutics market is segmented into surgery, chemotherapy, radiation therapy, and targeted therapy. The treatment of this cancer type often consists of a combination of radiation, chemotherapy, and targeted therapy.

Geographically, the market for pancreatic cancer therapeutics is distributed over North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Investment in research and development growing prevalence and increasing reach of novel techniques in the developing regions are the factors expected to drive the growth in these regions during the forecast period.

To obtain all-inclusive information on forecast analysis of Global Pancreatic Cancer Therapeutics Market, Request a PDF Brochure Here -

The pancreatic cancer therapeutics market is dominated by Gemzar (Gemcitabine) developed by Eli Lilly. Gemzar is indicated as first-line treatment of nonresectable (stage II or stage III) or metastatic (stage IV) adenocarcinoma of the pancreas. Gemzar and Tarceva (Erlotinib) by Genentech/OSI Pharmaceuticals/Roche account for a majority share of the global pancreatic cancer therapeutics market as these drugs have been in the market for a considerable time.

Abraxane by Celgene is another therapeutic drug that was launched in the U.S. and Europe in 2013 and 2014, respectively. Abraxane was the first drug to be approved for the pancreatic cancer treatment in almost a decade, and it is aggressively competing with existing drugs. A few pipeline drugs are expected to be launched toward the end of the forecast period. Numerous untapped opportunities in clinical development exist in the pancreatic cancer therapeutics market.

Major players operating in the market include Amgen, Inc., Genentech, Inc., Abraxis BioScience, LLC (Celgene Corporation), Pfizer Inc, Eli Lilly and Company, Novartis AG, and Threshold Pharmaceutic.


Mr. Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453

About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Pancreatic Cancer Therapeutics Market Overview and Regional Outlook Study here

News-ID: 1846446 • Views: 179

More Releases from Transparency Market Research

Food Premix Market Observe Substantial Growth by 2018-2026
Global Food Premix Market: Overview Globally, the parents are more conscious about their baby food. They prefer to give healthy and high nutritional content to their babies. This has led the demand in the global food premix market Read report Overview- Based on form and application are likely to be the key segments in which the market can be divided. Food & beverages, early life nutrition/ baby food, pharma OTC drugs, dietary supplements,
Calcium Silicate Market with Positive Long-Term Growth Outlook, 2016-2023
Calcium silicate, also known as calcium orthosilicate, is a white powder derived from diatomaceous earth and limestone. It is obtained by reacting calcium oxide and silica in various ratios. Calcium silicate possesses properties such as high physical water absorption and low bulk density. Due to these special physical characteristics calcium silicate has several applications in the construction sector. It is also used as a food additive in the food processing
Polysulfides Market Scope and Opportunities Analysis 2015– 2023
Polysulfides are chemical compounds that primarily comprise chains of sulfur atoms. These compounds exhibit various functional properties due to which they are chiefly consumed in building & construction, marine, aerospace, glass insulation, and polymer processing industries. Polysulfides possess high flexibility, high tensile strength, impermeability, chemical and weather resistance, and heat insulation. Read report Overview- Hence, they are favorably used in coating and sealing applications. These sulfur compounds are generally classified as anionic
CRISPR and Cas Genes Market Compnies Size, Future Trends, Segmentation, Gross Ma …
Transparency Market Research (TMR) has published a new report titled, “CRISPR and Cas Genes Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global CRISPR and Cas genes market was valued at US$ 7,234.5 Mn by 2026, expanding at a CAGR of around 20.1% from 2018 to 2026. Increase in applications of CRISPR and Cas gene editing technology in bacteria and usage

All 5 Releases

More Releases for Pancreatic

Exocrine Pancreatic Insufficiency (EPI) Therapeutics- Pipeline Analysis
Exocrine pancreatic insufficiency (EPI) is the inability of pancreas to produce enough enzymes for the proper breakdown and absorption of nutrients. The common causes of EPI are damage to pancreas, inflammation of pancreas, pancreatic surgery, and inherited disorders like Crohn’s disease and celiac disease. Download the sample report at: Some symptoms observed during EPI are pain or tenderness in belly, bad-smelling bowel movements, gas, diarrhea and feeling of fullness. EPI
Pancreatic Cancer Pipeline Review H1 2019
Pancreatic Cancer - Pipeline Review, H1 2017 Summary Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Pancreatic Cancer - Pipeline Review, H1 2017, provides an overview of the Pancreatic Cancer (Oncology) pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. This is also called exocrine cancer. Signs and symptoms include upper abdominal pain that may radiate to back, yellowing of skin and
Exocrine Pancreatic Insufficiency (EPI) Therapeutics Market Opportunity Analysis …
Exocrine pancreatic insufficiency (EPI) is a condition associated with deficiency of exocrine pancreatic enzymes that results in the inability to digest food or maldigestion. EPI may be associated with certain diseases and conditions that affect the pancreas such as cystic fibrosis, chronic pancreatitis, Shwachman–Diamond syndrome, and others. Chronic pancreatitis (CP) is the most common cause of EPI in adults that is followed by cystic fibrosis (CF). CF is an inherited
Pancreatic Cancer Pipeline Drugs Review H1 2017
Pancreatic Cancer Pipeline Review H1 2017 provides an overview of the Pancreatic Cancer (Oncology) therapeutics pipeline landscape. Pancreatic cancer is a disease in which malignant (cancer) cells are found in the tissues of the pancreas. Report provides comprehensive information on the therapeutics under development for Pancreatic Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide
Pancreatic Cancer Drug Pipeline Analysis
“Pancreatic Cancer Drug Pipeline Analysis” by PNS Pharma gives comprehensive insight on the various drug profiles being developed for the treatment of Pancreatic Cancer. Research report covers all the ongoing drug development in various phases. Each drug profiles include detailed information like: Originator, Owner, Collaborator, Technology Provider, Licensee, Development Phase, Development Indications, Mechanism of Action, Chemical Formula, Country of Development and detailed analysis on the development process. Insight for each
Exocrine Pancreatic Insufficiency Market 2013
Transparency Market Research has published a new market report titled, “Exocrine Pancreatic Insufficiency Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2013 – 2023.” According to the report, the exocrine pancreatic insufficiency market is anticipated to expand at a CAGR of 8.3% from 2015 to 2023 to reach US$2.85 Bn by 2023. Browse the full Exocrine Pancreatic Insufficiency Market – (Therapeutic – Pancreatic Enzyme Replacement Therapy (Creon, Zenpep,